Skip to content

US · LKFT · BIOTECHNOLOGY

Lakefront Biotherapeutics N.V. (LKFT) intrinsic value and stock valuation

$33.31as of 2026-11-21 · Mkt cap 1.72B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lakefront Biotherapeutics N.V. DCF and intrinsic value

InvestorsCraft values LKFT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LKFT’s statements →

Lakefront Biotherapeutics N.V. Graham Number

Graham Number: $73.35d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Mechelen 2800 galapagos.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$1.11B
20252025
Net income
$320.9M
20252025
Free cash flow
-$-271.31M
20252025
Total equity
$3.24B
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$1.11B
Operating income$501.4M
Net income$320.9M
EPSd$4.87M
Operating cash flow-$-257.46M
Capital expenditure-$-13.86M
Free cash flow-$-271.31M
Total assets$3.41B
Total debt$6.92M
Net debt-$-80.95M
Total equity$3.24B
Cash and short-term investments$3B
Income statement
2025
Revenue$1.11B
Cost of revenue$29.7M
Gross profit$1.08B
Research and development expenses$459.4M
Selling, general and administrative expenses$112M
Other expenses$9.74M
Operating expenses$581.1M
Cost and expenses$610.9M
Interest income$46.3M
Interest expense$2.22M
Depreciation and amortization$55.9M
Ebitda$359M
Operating income$501.4M
Total other income/expenses, net-$-200.52M
Income before tax$300.9M
Income tax expense-$-18.62M
Net income$320.9M
Weighted average shares outstanding$65.9M
Weighted average diluted shares outstanding$65.9M
Balance sheet
2025
Cash and short-term investments$3B
Net receivables$53.2M
Inventory$22.5M
Total current assets$3.08B
Property, plant and equipment, net$80.7M
Goodwill and intangible assets$850K
Long-term investments$46.8M
Total non-current assets$327.1M
Total assets$3.41B
Accounts payable$32.6M
Short-term debt$1.73M
Deferred revenue$30K
Total current liabilities$152.9M
Long-term debt$5.19M
Deferred revenue, non-current$0.00
Total non-current liabilities$17.8M
Capital lease obligations$6.92M
Total liabilities$170.7M
Common stock$293.9M
Retained earnings$210.6M
Accumulated other comprehensive income (loss)-$-5.64M
Total equity$3.24B
Total investments$2.96B
Total debt$6.92M
Net debt-$-80.95M
Cash flow statement
2025
Net income$320.9M
Depreciation and amortization$55.9M
Stock-based compensation$24M
Change in working capital-$-876.57M
Accounts receivable$86.6M
Inventory$28.9M
Accounts payable$0.00
Net cash provided by operating activities-$-257.46M
Investments in property, plant and equipment-$-13.7M
Acquisitions, net$19.4M
Net cash used for investing activities$288.8M
Common stock issued$0.00
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities-$-3.27M
Net change in cash$23.6M
Cash at end of period$87.9M
Operating cash flow-$-257.46M
Capital expenditure-$-13.86M
Free cash flow-$-271.31M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lakefront Biotherapeutics N.V.

        Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

        CEO
        Henry O. Gosebruch
        Employees
        452
        Beta
        0.12

        Explore

        Frequently asked questions

        What is the intrinsic value of Lakefront Biotherapeutics N.V. (LKFT)?

        InvestorsCraft does not currently publish an intrinsic value for LKFT. How the IC value is calculated.

        Is LKFT undervalued?

        InvestorsCraft does not publish an undervaluation signal for LKFT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.